Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Reneo Pharmaceuticals Inc (NQ: RPHM )

1.650 +0.030 (+1.85%)
Streaming Delayed Price Updated: 3:28 PM EDT, Sep 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Reneo Pharmaceuticals Inc

< Previous 1 2 Next >
Reneo Pharmaceuticals Announces Presentation and Posters at Mitochondrial Medicine Symposium 2023
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Update -- Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Announces Pricing of Public Offering of Common Stock
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar (REN001) in Primary Mitochondrial Myopathies
Topline data from the STRIDE study expected in the fourth quarter of 2023 
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals to Present Preclinical Mavodelpar (REN001) Data at the Society for Inherited Metabolic Disorders Annual Meeting 2023
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD)
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals Reports Third Quarter 2022 Financial Results
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development Updates
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.